Compare Charles River Laboratories Intl. Inc (CRL) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VanEck Junior Gold Miners — how do they compare? Charles River Laboratories Intl. Inc trades at $228.76 (market cap $11.14B), while VanEck Junior Gold Miners trades at $95.63. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| CRL | GDXJ | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $233.60 | $156.19 |
52-Week Low | $145.57 | $64.22 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GDXJ (VanEck Junior Gold Miners ETF) trades at $95.40, down 3.55% with a bearish technical signal from moving averages. The fund has underperformed peers in 2026 with double-digit declines while other mining ETFs gained. Technical indicators show neutral oscillators but bearish momentum with key support at $92 and resistance at $97. Recent news highlights concerns about the fund's small-cap exposure and portfolio overlap issues.
The outlook remains challenging given GDXJ's 2026 underperformance and technical bearishness. Investment opportunity exists for contrarian bets on gold miner recovery, but risks include Federal Reserve policy uncertainty, weak small-cap gold miner fundamentals, and continued underperformance versus senior mining peers. The fund's high overlap with larger miners reduces diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
